Trial Profile
A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Tapinarof (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ADORING 1
- Sponsors Dermavant Sciences
- 04 Mar 2024 According to a Dermavant Sciences media release, the company announced that new ADORING data including treatment of patients with skin of color from Phase 3 trials of VTAMA (tapinarof) cream, 1% in adults and children 2 years of age and older with atopic dermatitis will be presented at the 2024 American Academy of Dermatology Annual Meeting, to be held from March 8-12 in San Diego, California.
- 14 Feb 2024 According to a Dermavant Sciences media release, based on data from ADORING 1, 2, and 3, the company has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older.
- 11 Jan 2024 Results from this study presented in a Dermavant Sciences media release.